| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Laboratory of Cellular and Molecular Biology [G. P. S., C. A. S-B., P. J. M.] and DNA Array Unit [K. G. B., C. C., D. T.], Gerontology Research Center, National Institute on Aging, Baltimore Maryland 21224
Ovarian cancer is a major cause of cancer death in women. Unfortunately, the molecular pathways underlying ovarian cancer progression are poorly understood, making the development of novel diagnostic and therapeutic strategies difficult. On the basis of our previous observations obtained from serial analysis of gene expression, we have constructed a specialized cDNA array for the study of ovarian cancer. Small, specialized arrays have several practical advantages and can reveal information that is lost in the "noise" generated by irrelevant genes present in larger arrays. The array, which we named Ovachip, contains 516 cDNAs chosen from our serial analysis of gene expression and cDNA array studies for their relevance to ovarian cancer. The gene expression patterns revealed with the Ovachip are highly reproducible and extremely consistent among the different ovarian specimens tested. This array was extremely sensitive at differentiating ovarian cancer from colon cancer based on expression profiles. The Ovachip revealed clusters of coordinately expressed genes in ovarian cancer. One such cluster, the IGF2 cluster, is particularly striking and includes the insulin-like growth factor II, the cisplatin resistance-associated protein, the checkpoint suppressor 1, the cyclin-dependent kinase 6, and a protein tyrosine phosphatase receptor. We also identified a cluster of down-regulated genes that included the cyclin-dependent kinase 7 and cyclin H. Thus, the Ovachip allowed us to identify previously unidentified clusters of differentially expressed genes that may provide new paradigms for molecular pathways important in ovarian malignancies. Because of the relevance of the arrayed genes, the Ovachip may become a powerful tool for investigators in the field of ovarian cancer and may facilitate progress in understanding the etiology of this disease and in its clinical management.
This article has been cited by other articles:
![]() |
H. K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, R. Sayer, J. Cragun, J. Clarke, R. S. Whitaker, L. Li, et al. An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer J. Clin. Oncol., February 10, 2007; 25(5): 517 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. C. Shan, A. Scorilas, D. Katsaros, I. Rigault de la Longrais, M. Massobrio, and E. P. Diamandis Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols Clin. Chem., October 1, 2006; 52(10): 1879 - 1886. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Nambiar, S. R. Boutin, R. Raja, and D. W. Rosenberg Global Gene Expression Profiling: A Complement to Conventional Histopathologic Analysis of Neoplasia Vet. Pathol., November 1, 2005; 42(6): 735 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Nadon, D. Mohr, and K. G. Becker National Institute on Aging Microarray Facility--Resources for Gerontology Research J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2005; 60(4): 413 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Drapkin, H. H. von Horsten, Y. Lin, S. C. Mok, C. P. Crum, W. R. Welch, and J. L. Hecht Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas Cancer Res., March 15, 2005; 65(6): 2162 - 2169. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Hartmann, K. H. Lu, G. P. Linette, W. A. Cliby, K. R. Kalli, D. Gershenson, R. C. Bast, J. Stec, N. Iartchouk, D. I. Smith, et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy Clin. Cancer Res., March 15, 2005; 11(6): 2149 - 2155. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. McLaren, M. Mayne, S. Rosser, T. Moffatt, K. G. Becker, F. A. Plummer, and K. R. Fowke Antigen-Specific Gene Expression Profiles of Peripheral Blood Mononuclear Cells Do Not Reflect Those of T-Lymphocyte Subsets Clin. Vaccine Immunol., September 1, 2004; 11(5): 977 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Heinzelmann-Schwarz, M. Gardiner-Garden, S. M. Henshall, J. Scurry, R. A. Scolyer, M. J. Davies, M. Heinzelmann, L. H. Kalish, A. Bali, J. G. Kench, et al. Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer Clin. Cancer Res., July 1, 2004; 10(13): 4427 - 4436. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Mintzer, M. Warhol, A.-M. Martin, and G. Greene Cancer of Unknown Primary: Changing Approaches. A Multidisciplinary Case Presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital Oncologist, June 1, 2004; 9(3): 330 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Scorilas, C. A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker J. Clin. Oncol., February 15, 2004; 22(4): 678 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Lancaster, H. K. Dressman, R. S. Whitaker, L. Havrilesky, J. Gray, J. R. Marks, J. R. Nevins, and A. Berchuck Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers Reproductive Sciences, January 1, 2004; 11(1): 51 - 59. [Abstract] [PDF] |
||||
![]() |
P. Buckhaults, Z. Zhang, Y.-C. Chen, T.-L. Wang, B. St. Croix, S. Saha, A. Bardelli, P. J. Morin, K. Polyak, R. H. Hruban, et al. Identifying Tumor Origin Using a Gene Expression-based Classification Map Cancer Res., July 15, 2003; 63(14): 4144 - 4149. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. A. Rangel, R. Agarwal, T. D'Souza, E. S. Pizer, P. L. Alo, W. D. Lancaster, L. Gregoire, D. R. Schwartz, K. R. Cho, and P. J. Morin Tight Junction Proteins Claudin-3 and Claudin-4 Are Frequently Overexpressed in Ovarian Cancer but Not in Ovarian Cystadenomas Clin. Cancer Res., July 1, 2003; 9(7): 2567 - 2575. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Lamendola, Z. Duan, R. Z. Yusuf, and M. V. Seiden Molecular Description of Evolving Paclitaxel Resistance in the SKOV-3 Human Ovarian Carcinoma Cell Line Cancer Res., May 1, 2003; 63(9): 2200 - 2205. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |